Parkinsonism is the most commonly reported symptom of spinocerebellar ataxia, and so patients who solely present parkinsonism, should also have SCA considered as a possible diagnosis.

DENVER — Four studies presented at the American Academy of Neurology annual meeting show improvements in patients with spinocerebellar ataxia who take troriluzole.“SCAs [spinocerebellar ...

ANN ARBOR -- An abnormality discovered by University of Michigan researchers in mice with Spinocerebellar Ataxia type 3 could represent a target for therapy. In a paper published this week in the ...

More information: Tomohiko Ishihara et al, L-arginine in patients with spinocerebellar ataxia type 6: a multicentre, ...

The BH4157-206-RWE study evaluated the effectiveness of troriluzole after 3 years of treatment in patients with ... results-in-pivotal-study-of-troriluzole-in-spinocerebellar-ataxia-sca ...

The report provides a detailed analysis of the current spinocerebellar ataxia marketed drugs and late-stage pipeline drugs, ...

Patients with Spinocerebellar Ataxia often experience difficulties with walking, hand-eye coordination, speech (dysarthria), and in some cases, vision and cognitive function.

Spinocerebellar Ataxia (SCA) is a rare, genetic, life-threatening neurodegenerative disease with no available treatment. Troriluzole demonstrated a 50-70% slowing of SCA disease progression on the ...

Seelos Therapeutics Inc (NASDAQ: SEEL) temporarily pauses additional enrollment of patients in the SLS-005-302 study in spinocerebellar ataxia type 3 (SCA3). Patients already enrolled will ...

Stefan Pulst, a neurologist at the University of Utah, sees hundreds of patients each year with puzzling brain diseases.But 15 years ago, he met a patient whom he thought could be the key to solving a ...

Article Title. L-arginine in patients with spinocerebellar ataxia type 6: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial ...

The Spinocerebellar Ataxia pipeline is advancing fast as troriluzole nears FDA nod and rivals race with gene and stem cell therapies to seize market edge. Disease modification in spinocerebellar ...